
|Videos|September 17, 2021
Dr. Chamie on durability of UGN-101 in low-grade UTUC
Author(s)Urology Times staff
“The reason that [long-term follow up is] important is because if you look at the best of hands, the incidence of recurrence of upper tract urothelial carcinoma, even for low and intermediate risk, is still very high,” says Karim Chamie, MD.
Advertisement
In this video, Karim Chamie, MD, discusses the background of the study, “Long-term recurrence free survival following UGN-101 treatment for low-grade upper tract urothelial carcinoma,” presented at the 2021 American Urological Association Annual Meeting, and how it builds on previous studies. Chamie is an associate professor of urology and director of the Urologic Oncology Fellowship at the University of California, Los Angeles.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
FDA approves cefepime and zidebactam for complicated UTI
3
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
4
Enzalutamide associated with greater cognitive decline than darolutamide in advanced prostate cancer
5











